Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-AlF-NOTA-octreotide PET/CT in Neuroendocrine Neoplasms
NCT03511768Phase 2Unknown
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Jan 2018
- Primary completion
- Dec 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of 18F-AlF-NOTA-octreotide in Neuroendocrine neoplasm (NEN), sponsored by Xiangya Hospital, Central South University. Primary endpoint: 18F-AlF-NOTA-octreotide PET/CT imaging at 12 months. Status: unknown.
02
Drugs
18F-AlF-NOTA-octreotide
03
Conditions
Neuroendocrine neoplasm (NEN)
Beyond the preview
Go deeper on NCT03511768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03511768.